Ocata Therapeutics Inc fka OCAT

[rocky301]

Focus and Strategy for 2013

Our focus and strategy are clear. In 2013 we plan to build on the growing awareness of the promise of regenerative medicine to make it the best year not only in this field but in the company’s history, as well. This year we hope to achieve a number of specific milestones, including:

•Reverse stock split and up-listing of our stock to NASDAQ
•Completion of both of our Phase I trials for Stargardt’s Disease in the U.S. and Europe, and our Phase I trial for dry age-related macular degeneration (dry AMD)
•Sharing final Phase I trial results with our followers
•New developments involving our various initiatives in Europe
•Initiation of our Induced Pluripotent Stem (iPS) Cell-Derived Human Platelet Program
•Initiation of three Phase II trials for SMD and dry AMD
•Initiation of clinical trial for myopia
http://www.thechairmansblog.com/gary-rabin/2013-01/2013-the-year-regenerative-medicine-hits-its-stride.html